{"filing":{"accession_number":"0000200406-26-000167","cik":"0000200406","ticker":"JNJ","company_name":"JOHNSON \u0026 JOHNSON","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"jnj-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/200406/000020040626000167/jnj-20260804.htm"},"events":[{"id":23781,"run_id":21508,"accession_number":"0000200406-26-000167","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine (a $60+ billion business unit) and Executive Committee member, is retiring effective September 1, 2026. While the filing also discloses Tom Cavanaugh's appointment as her successor, the principal disclosed action centers on Taubert's departure from a senior executive role after 21 years. The appointment is presented as a succession event, making the departure the salient event.","company_name":"JOHNSON \u0026 JOHNSON","ticker":"JNJ","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24110,"accession_number":"0000200406-26-000167","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine (a $60+ billion business unit) and Executive Committee member, is retiring effective September 1, 2026. While the filing also discloses Tom Cavanaugh's appointment as her successor, the principal disclosed action centers on Taubert's departure from a senior executive role after 21 years. The appointment is presented as a succession event, making the departure the salient event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:16:36.962745+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24110,"accession_number":"0000200406-26-000167","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine (a $60+ billion business unit) and Executive Committee member, is retiring effective September 1, 2026. While the filing also discloses Tom Cavanaugh's appointment as her successor, the principal disclosed action centers on Taubert's departure from a senior executive role after 21 years. The appointment is presented as a succession event, making the departure the salient event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:16:36.962745+00:00","company_name":"JOHNSON \u0026 JOHNSON","ticker":"JNJ","filing_date":"2026-08-04"}]}